6'-O-galloylpaeoniflorin alleviates inflammation and oxidative stress in pediatric pneumonia through activating Nrf2 activation
Allergol. immunopatol
; 50(4): 71-76, jul. 2022. graf
Article
in English
| IBECS
| ID: ibc-208896
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Objective:
To assess the therapeutic effect and mechanism of 6'-o-galloylpaeoniflorin (GPF) in pediatric pneumonia.Methods:
The effects of lipopolysaccharide (LPS) and GPF on cell viability and apoptosis were examined by cell counting kit-8 assay and flow cytometry analysis. The oxidative stress and inflammatory response were assessed by detecting expression levels of superoxide dismutase, glutathione, r-glutamyl cysteingl+glycine, myeloperoxidase, and malondialdehyde as well as tumor necrosis factor-α, Interleukin-18, and Interleukin-10 by using enzyme-linked-immuno-sorbent serologic assay. Moreover, the activation of nuclear factor erythroid 2-related factor 2 (Nrf2) pathway was detected by immunoblot assay, and the influence of Nrf2-knockdown on cell viability, oxidative stress, and inflammation response was also investigated.Results:
The results established that GPF increased the viability of LPS-induced pneumonia cells. In addition, GPF reduced LPS-induced oxidative stress in pneumonia cells. It was further discovered that GPF reduced LPS-induced inflammation in pneumonic cell. GPF improved the activity of Nrf2 in LPS-treated pneumonic cells, and therefore alleviated inflammation and oxidative stress in pediatric pneumonia.Conclusion:
GPF could serve as a promising drug for treating pediatric pneumonia (AU)
Full text:
Available
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Pneumonia
/
Lipopolysaccharides
/
NF-E2 Transcription Factor
Limits:
Child
/
Humans
Language:
English
Journal:
Allergol. immunopatol
Year:
2022
Document type:
Article
Institution/Affiliation country:
Nantong First People's Hospital (The Second Affiliated Hospital of Nantong University)/China